BioXcel Therapeutics wins court approval for bankruptcy asset sale to Teva
Bitget2026/10/30 21:16- A bankruptcy court cleared BioXcel Therapeutics' asset sale to Teva Pharmaceuticals International, allowing the transaction to close immediately.
- Consideration includes a $57.5 million upfront payment, subject to adjustments, with additional payments contingent on development and commercial milestones.
- Teva will assume specified liabilities, with its contract cure-cost obligation capped at $2.5 million.
- The assets will transfer free of liens and claims, except permitted encumbrances and assumed liabilities.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Honda Motor (HMC.US) Reports 65.7% Increase in Net Profit in the First Half, Plans to Expand Production Capacity in North America and Brazil
Honda Motor (HMC.US) released its financial results for the first half of fiscal year 2027 on November 10.
Crypto winter not over? Mining rig hosting provider Bitari cancels orders at the last minute, IPO plans put on hold
Bitcoin mining service provider Bitari has withdrawn its Nasdaq IPO plan. The company originally intended to issue 4.3 million shares at $7 per share to raise $30 million. Its annual revenue is approximately $11 million.
Pre-orders for GTA 6 are booming and may reverse the downward trend! Citigroup raises Take-Two Interactive Software (TTWO.US) target to $270
Citigroup maintains a "Buy" rating on Take-Two Interactive Software, with a target price of $270.
Crypto prices
More
